Clinical trial · Observational
An Exploratory Study of ctDNA-MRD in Predicting the Efficacy of Esophageal Squamous Cell Carcinoma
Application of ctDNA-MRD in the Prediction of Curative Effect, Recurrence Monitoring and Prognosis Evaluation of Esophageal Squamous Cell Carcinoma (ESCC) During Perioperative Treatment
NCT05759325CI-TRIAL-00064540not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to observe and evaluate the correlation between ctDNA-MRD and the therapeutic effect and prognosis of stage II-IVA operable esophageal squamous cell carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Squamous Cell Carcinoma of Esophagus | Esophageal Squamous Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- up to 2 year
- description
- Evaluation of progression-free survival rate of esophageal squamous cell carcinoma patients with different MRD status during perioperative period
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with stage II-IVA Esophageal squamous cell carcinoma confirmed by clinical pathological staging; 2. ≥18 years; 3. Eastern Cooperative Oncology Group performance status score (ECOG PS) is 0 \~ 1 points; 4. Expected survival time ≥ 6 months; 5. Patients agree and have the ability to follow the planned study visits, laboratory tests and other research steps. Exclusion Criteria: 1. Patients with other malignant tumors; 2. Patient had undergone surgery before admission; 3. Pregnant or lactating women; 4. Patients with other serious diseases; 5. Patients who could not understand the experiment content and could not cooperate with them and refused to sign the informed consent form; 6. Patients with contraindications to radiotherapy and chemotherapy; 7. Other researchers think it is not suitable.
References
Publications (0)
Data not yet available
No reference posted for this study.